Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.

Regenerative Medicine, published by Taylor & Francis Ltd, is a pivotal journal within the field of biomedical research, focusing on the innovative advances in regenerative and restored functions in human health. With an ISSN of 1746-0751 and an E-ISSN of 1746-076X, this esteemed journal boasts a commendable impact factor within its categories, notably holding the Q2 status in Embryology and Q3 in Biomedical Engineering as of 2023. Covering a broad spectrum of topics from stem cell research to tissue engineering, it serves as a crucial platform for interdisciplinary collaboration among researchers, professionals, and students dedicated to the regeneration of tissues and organs. Given its comprehensive scope from 2006 to 2024, the journal continues to attract high-quality manuscripts that advance the frontiers of knowledge in regenerative medicine. Researchers and practitioners alike are encouraged to engage with the latest findings and methodologies disseminated in this vital publication.

Stem Cell Research & Therapy is an esteemed international journal published by BMC, specializing in the rapidly advancing fields of stem cell research and regenerative therapies. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that vital research is readily accessible to a global audience. With a significant impact in the scientific community, it holds Q1 quartile rankings in prestigious categories such as Biochemistry, Genetics and Molecular Biology, Cell Biology, and Molecular Medicine, highlighting its critical role in promoting groundbreaking research. The journal’s high Scopus rankings—placing it in the top echelons of its fields—reflect its commitment to publishing high-quality, peer-reviewed studies that advance our understanding of stem cell biology and therapeutic applications. Aimed at researchers, healthcare professionals, and students alike, Stem Cell Research & Therapy is an indispensable resource for those dedicated to the exploration and innovation within this transformative area of science.

The Journal of Stem Cells & Regenerative Medicine is a leading publication dedicated to the advancing field of stem cell research and regenerative medicine. Established in India and published by JOURNAL STEM CELLS & REGENERATIVE MEDICINE, this Open Access journal has been available since 2007, providing researchers and practitioners with free and unrestricted access to high-quality articles. With an ISSN of 0973-7154, the journal is indexed in Scopus, featuring a wide array of topics and insights into biochemistry, biotechnology, cell biology, and molecular biology, as denoted by its relevant quartile rankings. This journal is committed to bridging the gap between laboratory research and clinical applications, making significant contributions to the scientific community. The convergence of innovative studies from 2010 to 2024 positions it as an invaluable resource for those looking to stay at the forefront of stem cell and regenerative medicine research.

Journal of Tissue Engineering and Regenerative Medicine, published by WILEY, stands as a pivotal platform in the fields of biomaterials, biomedical engineering, and regenerative medicine. With an ISSN of 1932-6254 and an E-ISSN of 1932-7005, this journal, based in the United Kingdom, has consistently delivered high-quality research since its inception in 2006, converging critical insights through 2024. With an impressive citation profile reflected in its Scopus rankings—specifically a rank of #58 in Medicine and #75 in Biomedical Engineering—the journal is acknowledged for its substantial impact, as demonstrated by its competitive quartile standings in 2023. Notably, it maintains a Q3 ranking in Biomaterials and Q2 in both Biomedical Engineering and Medicine (miscellaneous), showcasing its influence and relevance in the rapidly evolving interplay between engineering and medicine. The journal serves as a vital resource for researchers and practitioners aiming to stay abreast of innovations and breakthroughs in regenerative therapies, tissue scaffolds, and biomaterials. While not an open-access publication, it fosters academic dialogue and knowledge dissemination that is crucial for advancing the field.

CELLS TISSUES ORGANS is a renowned academic journal published by KARGER, focusing on pivotal research within the fields of Anatomy and Histology. Based in Switzerland, this journal has been disseminating influential scientific findings since 1889, contributing to our understanding of cellular structures and tissue functionality. With a current impact factor that places it in the Q2 quartile for both disciplines, it serves as a vital resource for researchers, professionals, and students seeking to stay abreast of significant advancements and discussions in these areas. The journal embraces an Open Access model, ensuring that high-quality, peer-reviewed articles are freely available, thus enhancing visibility and accessibility of critical research. As it continues to foster scholarly communication and innovation up to 2024, CELLS TISSUES ORGANS plays a crucial role in shaping the future of biological sciences and medical research.

Organogenesis is a leading journal published by Taylor & Francis Inc, dedicated to advancing the field of developmental biology and regenerative medicine. With an ISSN of 1547-6278 and E-ISSN 1555-8592, this journal spans an extensive research scope that includes embryology, transplantation, and biomedical engineering, distinguishing itself as a crucial platform for researchers and practitioners alike. Its impact is reflected in its performance across various categories in 2023, earning Q3 rankings in Biomedical Engineering and Embryology, Q4 in Developmental Biology, and Q2 in Transplantation, showcasing its reputable standing among peer journals. Moreover, with Scopus rankings indicating strong positioning in the fields of medicine and biochemistry, Organogenesis is essential for those looking to publish or stay updated on pioneering research. The journal facilitates rigorous peer-review and offers a forum for disseminating innovative findings, making it an invaluable resource for academics, professionals, and students committed to understanding the complexities of organism development.

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.